Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus

Elena V. Shashkova, Shannon M. May, Konstantin Doronin, Michael A Barry

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

One of the significant hurdles toward safe and efficacious systemic treatment of cancer with oncolytic adenoviruses (Ads) is dose-limiting hepatotoxicity that prevents the increase of a therapeutic dose. In this study, we expanded the therapeutic window of oncolytic serotype 5 Ad (Ad5) by a genetic modification of hypervariable loop 5 (HVR5) in the capsid protein hexon that prevented infection of hepatocytes due to ablation of binding to blood factors. This oncolytic virus, Ad-GL-HB, had significantly reduced levels of hepatocyte transduction in immunocompetent and immunodeficient mice as compared to parental virus Ad-GL. The hepatocyte detargeting decreased liver damage and increased the maximum tolerated dose of Ad-GL-HB tenfold relative to that of Ad-GL. Intravenous (i.v.) injection of Ad-GL or Ad-GL-HB into tumor-bearing mice produced equally increased survival rates demonstrating that while Ad-GL-HB detargeted hepatocytes, it sustained tumor cell infection after systemic administration. The significantly improved safety of the virus allowed it to be used at increased doses for improved systemic antitumor efficacy. Our results suggest that hexon modifications provide valuable strategies forsystemic oncolytic Ad therapy.

Original languageEnglish (US)
Pages (from-to)2121-2130
Number of pages10
JournalMolecular Therapy
Volume17
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Adenoviridae
Hepatocytes
Oncolytic Viruses
Viruses
Neoplasms
Maximum Tolerated Dose
Capsid Proteins
Therapeutics
Infection
Intravenous Injections
Safety
Liver

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. / Shashkova, Elena V.; May, Shannon M.; Doronin, Konstantin; Barry, Michael A.

In: Molecular Therapy, Vol. 17, No. 12, 12.2009, p. 2121-2130.

Research output: Contribution to journalArticle

Shashkova, Elena V. ; May, Shannon M. ; Doronin, Konstantin ; Barry, Michael A. / Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. In: Molecular Therapy. 2009 ; Vol. 17, No. 12. pp. 2121-2130.
@article{dcff5bb548714b10ae1ff0cab2231766,
title = "Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus",
abstract = "One of the significant hurdles toward safe and efficacious systemic treatment of cancer with oncolytic adenoviruses (Ads) is dose-limiting hepatotoxicity that prevents the increase of a therapeutic dose. In this study, we expanded the therapeutic window of oncolytic serotype 5 Ad (Ad5) by a genetic modification of hypervariable loop 5 (HVR5) in the capsid protein hexon that prevented infection of hepatocytes due to ablation of binding to blood factors. This oncolytic virus, Ad-GL-HB, had significantly reduced levels of hepatocyte transduction in immunocompetent and immunodeficient mice as compared to parental virus Ad-GL. The hepatocyte detargeting decreased liver damage and increased the maximum tolerated dose of Ad-GL-HB tenfold relative to that of Ad-GL. Intravenous (i.v.) injection of Ad-GL or Ad-GL-HB into tumor-bearing mice produced equally increased survival rates demonstrating that while Ad-GL-HB detargeted hepatocytes, it sustained tumor cell infection after systemic administration. The significantly improved safety of the virus allowed it to be used at increased doses for improved systemic antitumor efficacy. Our results suggest that hexon modifications provide valuable strategies forsystemic oncolytic Ad therapy.",
author = "Shashkova, {Elena V.} and May, {Shannon M.} and Konstantin Doronin and Barry, {Michael A}",
year = "2009",
month = "12",
doi = "10.1038/mt.2009.217",
language = "English (US)",
volume = "17",
pages = "2121--2130",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus

AU - Shashkova, Elena V.

AU - May, Shannon M.

AU - Doronin, Konstantin

AU - Barry, Michael A

PY - 2009/12

Y1 - 2009/12

N2 - One of the significant hurdles toward safe and efficacious systemic treatment of cancer with oncolytic adenoviruses (Ads) is dose-limiting hepatotoxicity that prevents the increase of a therapeutic dose. In this study, we expanded the therapeutic window of oncolytic serotype 5 Ad (Ad5) by a genetic modification of hypervariable loop 5 (HVR5) in the capsid protein hexon that prevented infection of hepatocytes due to ablation of binding to blood factors. This oncolytic virus, Ad-GL-HB, had significantly reduced levels of hepatocyte transduction in immunocompetent and immunodeficient mice as compared to parental virus Ad-GL. The hepatocyte detargeting decreased liver damage and increased the maximum tolerated dose of Ad-GL-HB tenfold relative to that of Ad-GL. Intravenous (i.v.) injection of Ad-GL or Ad-GL-HB into tumor-bearing mice produced equally increased survival rates demonstrating that while Ad-GL-HB detargeted hepatocytes, it sustained tumor cell infection after systemic administration. The significantly improved safety of the virus allowed it to be used at increased doses for improved systemic antitumor efficacy. Our results suggest that hexon modifications provide valuable strategies forsystemic oncolytic Ad therapy.

AB - One of the significant hurdles toward safe and efficacious systemic treatment of cancer with oncolytic adenoviruses (Ads) is dose-limiting hepatotoxicity that prevents the increase of a therapeutic dose. In this study, we expanded the therapeutic window of oncolytic serotype 5 Ad (Ad5) by a genetic modification of hypervariable loop 5 (HVR5) in the capsid protein hexon that prevented infection of hepatocytes due to ablation of binding to blood factors. This oncolytic virus, Ad-GL-HB, had significantly reduced levels of hepatocyte transduction in immunocompetent and immunodeficient mice as compared to parental virus Ad-GL. The hepatocyte detargeting decreased liver damage and increased the maximum tolerated dose of Ad-GL-HB tenfold relative to that of Ad-GL. Intravenous (i.v.) injection of Ad-GL or Ad-GL-HB into tumor-bearing mice produced equally increased survival rates demonstrating that while Ad-GL-HB detargeted hepatocytes, it sustained tumor cell infection after systemic administration. The significantly improved safety of the virus allowed it to be used at increased doses for improved systemic antitumor efficacy. Our results suggest that hexon modifications provide valuable strategies forsystemic oncolytic Ad therapy.

UR - http://www.scopus.com/inward/record.url?scp=73849140058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849140058&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.217

DO - 10.1038/mt.2009.217

M3 - Article

C2 - 19755961

AN - SCOPUS:73849140058

VL - 17

SP - 2121

EP - 2130

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 12

ER -